


AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof.



wherein

m represents 0, 1, 2, or 3;

p represents 0, 1, 2, or 3;

-X- represents a bond, -O- or -N(R¹⁰)- (wherein R¹⁰ is hydrogen or C₁₋₆ alkyl);

with the proviso that when m is 0, -X- represents a bond,

R^A and R^B represent hydrogen,

or

R^A and R^B together form a carbonyl-group with the carbon-atom to which they are connected ,

R¹ represents aryl or heteroaryl

wherein said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkyl carbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by

halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle; and

R² represent C₁₋₆ alkyl carbonyl, C₁₋₆ alkylsulfonyl, hydrogen, hydroxy, aryl, heteroaryl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, arylsulfonyl, or heteroaryl sulfonyl,

wherein

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₃₋₈ cycloalkyl, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(aryl)-amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆ alkyl)aminocarbonyl, or N,N-di(C₁₋₆ alkyl)aminocarbonyl, and

said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroaryl sulfonyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C₁₋₆ alkoxy)carbonyl, C₃₋₈ cycloalkyl, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆ alkyl)aminocarbonyl, N,N-di(C₁₋₆ alkyl)aminocarbonyl, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-halogen, or C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri-halogen.

2. (Previously Presented) The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

m represents 0, 1, 2, or 3;

p represents 0, 1, 2, or 3;

-X- represents a bond, -O- or -N(R¹⁰)- (wherein R¹⁰ is hydrogen or C₁₋₆ alkyl);
with the proviso that when m is 0, -X- represents a bond,

R^A and R^B represent hydrogen,

R¹ represents aryl or heteroaryl

wherein said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which

Amendment dated December 23, 2008
Reply to Office Action of September 25, 2008

phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkyl carbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle; and

R² represent C₁₋₆ alkyl carbonyl, C₁₋₆ alkyl sulfonyl, hydrogen, hydroxy, aryl, heteroaryl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, arylsulfonyl, or heteroarylsulfonyl,

wherein

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C₁₋₆ alkoxy, C₁₋₆ alkoxy carbonyl, C₃₋₈ cycloalkyl, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(aryl)-amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆ alkyl)aminocarbonyl, or N,N-di(C₁₋₆ alkyl)aminocarbonyl, and

said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C₁₋₆ alkoxy) carbonyl, C₃₋₈ cycloalkyl, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆ alkyl)aminocarbonyl, N,N-di(C₁₋₆ alkyl)aminocarbonyl, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-halogen, or C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri-halogen.

3. (Previously Presented) The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

m represents 0, 1, 2, or 3;

p represents 0, 1, 2, or 3;

-X- represents a bond, -O- or -N(R¹⁰)- (wherein R¹⁰ is hydrogen or C₁₋₆ alkyl);

with the proviso that when m is 0, -X- represents a bond,

R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle; and

R² represent C₁₋₆ alkyl carbonyl, C₁₋₆ alkylsulfonyl, hydrogen, hydroxy, aryl, heteroaryl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, arylsulfonyl, or heteroarylsulfonyl,

wherein

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C₁₋₆ alkoxy, C₁₋₆ alkoxy carbonyl, C₃₋₈ cycloalkyl, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆ alkyl)aminocarbonyl, or N,N-di(C₁₋₆ alkyl)aminocarbonyl, and

said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C₁₋₆ alkoxy) carbonyl, C₃₋₈ cycloalkyl, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆ alkyl)aminocarbonyl, N,N-di(C₁₋₆ alkyl)aminocarbonyl, C₁₋₆ alkyl optionally

substituted by mono-, di-, or tri-halogen, or C₁₋₆alkoxy optionally substituted by mono-, di-, or tri-halogen.

4. (Previously Presented) The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

m represents 0, 1, 2, or 3;

p represents 0, 1, 2, or 3;

-X- represents a bond, -O- or -N(R¹⁰)- (wherein R¹⁰ is hydrogen or C₁₋₆ alkyl);

with the proviso that when m is 0, -X- represents a bond,

R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle; and

R² represent C₁₋₆alkylcarbonyl, C₁₋₆alkylsulfonyl, hydrogen, hydroxy,

phenyl, naphthyl, pyridyl, pyrimidyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, phenylsulfonyl, pyrimidylsulfonyl, or pyridylsulfonyl,

wherein

Amendment dated December 23, 2008
Reply to Office Action of September 25, 2008

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C₁₋₆alkoxy, C₁₋₆alkoxycarbonyl, C₃₋₈cycloalkyl, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(aryl)-amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆alkyl)aminocarbonyl, or N,N-di(C₁₋₆alkyl)aminocarbonyl, and

said cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidyl, phnyl moiety, pyridyl moiety or pyrimidyl moiety of said phenylsulfonyl, pyridylsulfonyl, pyrimidylsulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C₁₋₆alkoxy)carbonyl, C₃₋₈cycloalkyl, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆alkyl)aminocarbonyl, N,N-di(C₁₋₆alkyl)aminocarbonyl, C₁₋₆alkyl optionally substituted by mono-, di-, or tri-halogen, or C₁₋₆alkoxy optionally substituted by mono-, di-, or tri-halogen.

5. (Previously Presented) The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

m represents 0, 1, 2, or 3;

p represents 0;

-X- represents a bond;

R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by

Amendment dated December 23, 2008
Reply to Office Action of September 25, 2008

halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle; and

- R² represent C₁₋₆ alkyl carbonyl, C₁₋₆ alkylsulfonyl, hydrogen, hydroxy, phenyl, naphthyl, pyridyl, pyrimidyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, phenylsulfonyl, pyrimidylsulfonyl, or pyridylsulfonyl,

wherein

said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C₁ alkoxy, C₁ alkoxy carbonyl, C₃₋₈ cycloalkyl, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆ alkyl)aminocarbonyl, or N,N-di(C₁₋₆ alkyl)aminocarbonyl, and

said cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidyl, phnyl moiety, pyridyl moiety or pyrimidyl moiety of said phenylsulfonyl, pyridylsulfonyl, pyrimidylsulfonyl are optionally substituted by

mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C₁ alkoxy)carbonyl, C₃₋₈ cycloalkyl, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆ alkyl)aminocarbonyl, N,N-di(C₁₋₆ alkyl)aminocarbonyl, C₁₋₆ alkyl optionally substituted by mono-, di-, or tri-halogen, or C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri-halogen.

6. (Previously Presented) The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

m represents 1,2, or 3;

p represents 0, 1, 2, or 3;

-X- represents bond, -O- or -N(R¹⁰)- (wherein R¹⁰ is hydrogen or C₁₋₆ alkyl);

R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino,

Amendment dated December 23, 2008
Reply to Office Action of September 25, 2008

di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle; and

R² represent C₁₋₆ alkyl carbonyl, C₁₋₆ alkylsulfonyl, hydrogen, hydroxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, or C₃₋₈ cycloalkyl,

wherein

said alkyl, alkenyl cycloalkyl, or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C₁₋₆ alkoxy, C₁₋₆ alkoxy carbonyl, C₃₋₈ cycloalkyl, amino, N-(C₁₋₆ alkyl)amino, N,N-di(C₁₋₆ alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆ alkyl)aminocarbonyl, or N,N,-di(C₁₋₆ alkyl)aminocarbonyl.

7. (Previously Presented) The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

m represents 0;

p represents 0;

-X- represents -O- or -N(R¹⁰)- (wherein R¹⁰ is hydrogen or C₁₋₆ alkyl);

R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl

Amendment dated December 23, 2008
 Reply to Office Action of September 25, 2008

(which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle; and

R² represent C₁₋₆alkylcarbonyl, C₁₋₆alkylsulfonyl, hydrogen, hydroxy, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, or C₃₋₈cycloalkyl,

wherein

said alkyl, alkenyl cycloalkyl, or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C₁₋₆alkoxy, C₁₋₆alkoxycarbonyl, C₃₋₈cycloalkyl, amino, N-(C₁₋₆alkyl)amino, N,N-di(C₁₋₆alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N-(C₁₋₆alkyl)aminocarbonyl, or N,N,-di(C₁₋₆alkyl)aminocarbonyl.

8. (Previously presented) The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

m represents 1,2, or 3;

p represents 0, 1, 2, or 3;

-X- represents bond, -O- or -N(R¹⁰)- (wherein R¹⁰ is hydrogen or C₁₋₆ alkyl);

R^A and R^B represent hydrogen,

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl and pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy,

Amendment dated December 23, 2008
Reply to Office Action of September 25, 2008

amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle; and

R² represent hydrogen, hydroxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, or C₃₋₈ cycloalkyl,

9. (Previously Presented) The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

R¹ represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein said phenyl, naphthyl, pyridyl, or pyrimidyl is optionally substituted by one or more of substituents selected from the group consisting of chloro, bromo, fluoro, nitro, methoxy, trifluoromethyl, trifluoromethoxy and C₁₋₆ alkanoylamino.

10. (Previously Presented) The urea derivative of formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said urea derivative of the formula (I) is selected from the group consisting of:

N-(4-chlorophenyl)-N'-(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)urea;

N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)urea;

N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(3-hydroxy-1,2,3,4-tetrahydroquinolin-5-yl)urea;

ethyl 3-({[(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)amino]carbonyl}amino)benzoate;

N-biphenyl-3-yl-N'-(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)urea.

and

the salts thereof.

Amendment dated December 23, 2008
Reply to Office Action of September 25, 2008

11. (Previously Presented) A pharmaceutical composition comprising a urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.
12. (Previously Presented) The pharmaceutical composition as claimed in claim 11, further comprising one or more pharmaceutically acceptable excipients.
13. (Previously Presented) The pharmaceutical composition as claimed in claim 11, wherein said urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.
14. (Currently Amended) A method for the treatment and/or prevention of an urological disorder or disease comprising administering to a subject in need thereof of a therapeutically effective amount of at least one urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.
15. (Previously Presented) The method as claimed in claim 14, wherein said urological disorder or disease is detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, or lower urinary tract symptoms.
16. (Currently Amended) A method for the treatment and/or prevention of pain comprising administering to a subject in need thereof of a therapeutically effective amount of at least one urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.
17. (Previously Presented) The method as claimed in claim 16, wherein said pain is chronic pain, neuropathic pain, postoperative pain, or rheumatoid arthritic pain.
18. (Currently Amended) A method for the treatment and/or prevention of a disorder or disease related to pain comprising administering to a subject in need thereof of a therapeutically effective amount of at least one urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.
19. (Previously Presented) The method as claimed in claim 18, wherein said disorder or disease related to pain is neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, or stroke.
20. (Currently Amended) A method for the treatment and/or prevention of an inflammatory disorder or disease comprising administering to a subject in need thereof of a therapeutically effective amount of at least one urea derivative of formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1.

21. (Previously Presented) The method as claimed in claim 20, wherein said inflammatory disorder or disease is asthma or COPD.

22 – 27. (Canceled)